459 Views

Session: Double Trouble: How Viruses and Bacterial Interactions Affect the Pathogenesis of Pneumonia

1496 - COVID-19 and Bacterial Co-Infection

Friday, October 21, 2022

2:35 PM – 3:00 PM US ET

Location: 201

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Speaker(s)

Richard G. Wunderink, MD

Professor of Medicine, Pulmonary and Critical Care
Northwestern University Feinberg School of Medicine
Chicago, IL, United States

Disclosure: Disclosure(s): Bioaegis: Advisor/Consultant (Ongoing); bioMerieux Inc.: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Helixbind: Grant/Research Support (Ongoing); LaJolla Pharmaceutical: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Microbiotix: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer, Inc.: Clinical Evaluation Committee (Ongoing); Shionogi & Co.,Ltd.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Synairgen: Advisor/Consultant (Ongoing); Venatorx Pharmaceuticals, Inc.: Advisor/Consultant (Terminated); Vir Biotechnology: DSMB (Ongoing)

Disclosure(s):

Richard G. Wunderink, MD: Bioaegis: Advisor/Consultant (Ongoing); bioMerieux Inc.: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Helixbind: Grant/Research Support (Ongoing); LaJolla Pharmaceutical: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Microbiotix: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer, Inc.: Clinical Evaluation Committee (Ongoing); Shionogi & Co.,Ltd.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Synairgen: Advisor/Consultant (Ongoing); Venatorx Pharmaceuticals, Inc.: Advisor/Consultant (Terminated); Vir Biotechnology: DSMB (Ongoing)